Publications

  • Maynard JP, Sfanos KS. P2 purinergic receptor dysregulation in urologic disease. Purinergic Signalling. 2022/06. doi: 10.1007/s11302-022-09875-1.
  • Peiffer LB, Hicks J, Sosa RY, De Marzo AM, Sfanos KS and Maynard JP. Modeling Human Prostate Cancer Metastasis in Mice via Resection of Subcutaneous Allografts. Front. Oncol. 2022;12:877536. doi: 10.3389/fonc.2022.877536
  • Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. J Pathol. 2022 Feb;256(2):149-163. doi: 10.1002/path.5815
  • Vidal I, Zheng Q, Hicks JL, Chen J, Platz EA, Trock BJ, Kulac I, Valle JB, Sfanos KS, Ernst S, Jones T, Maynard JP, Glavaris S, Nelson WG, Yegnasubramanian S, De Marzo AM. GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. PLoS One. 2021 Jun 30;16(6):e0241934.
  • Lopez-Bujanda ZA, Haffner MC, Chaimowitz MG, Chowdhury N, Venturini NJ, Patel RA, Obradovic A, Hansen CS, Jacków J, Maynard JP, Sfanos KS, Abate-Shen C, Bieberich CJ, Hurley PJ, Selby MJ, Korman AJ, Christiano AM, De Marzo AM, Drake CG. Castration-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer Progression.  Nat Cancer (2021). doi.org/10.1038/s43018-021-00227-3
  • Sullivan H, Maynard JP, Heaphy C, Lu J, De Marzo AM, Lotan T, Joshu C, Sfanos KS. Differential Mast Cell Phenotypes in Benign versus Cancer Tissues and Prostate Cancer Oncologic Outcomes. J. Pathol., 2021:253: 415-426.
  • Shrestha E, Coulter J, Guzman W, Ozbek B, Mummert L, Ernst S, Maynard JP, Meeker A, Heaphy C, Haffner M, De Marzo AM, Sfanos KS. Oncogenic gene fusions in non-neoplastic precursors as evidence that bacterial infection initiates prostate cancer. Proc Natl Acad Sci U S A. 2021 10;118(32):e2018976118. doi: 10.1073/pnas.2018976118
  • Maynard JP, Ertunc O, Kulac I, Baena-Del Valle JA, De Marzo AM, Sfanos KS. Interleukin-8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol Cancer Res. 2020;18(1):153-165.
  • Porter CM, Haffner MC, Kulac I, Maynard JP, Baena Del Valle JA, IsaacsWB, Yegnasubramanian S, De Marzo AM, Sfanos KS. Lactoferrin CpG island hypermethylation and decoupling of mRNA and protein expression in the early stages of prostate carcinogenesis. Am J Pathol. 2019;189(11):2311-2322.
  • Yu SH, Maynard JP, Vaghasia AM, De Marzo AM, Drake CG, Sfanos KS. A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth. The Prostate. 2019;79:215-222.
  • Maynard JP, Lee J, Sohn BH, Yu X, Lopez-Terrada D, Finegold MJ, Goss JA, Thevananther S. P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget. 2015;6(38):41162-41179.
  • Tackett BC, Sun H, Mei Y, Maynard JP, Cheruvu S, Mani A, Hernandez-Garcia A, Vigneswaran N, Karpen SJ, ThevanantherS. P2Y2 purinergic receptor activation is essential for efficient hepatocyte proliferation in response to partial hepatectomy. Am J Physiol Gastrointest Liver Physiol. 2014;307(11): G1073-1087.

Complete Publication List